Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · IEX Real-Time Price · USD
0.471
+0.061 (14.95%)
At close: May 31, 2024, 4:00 PM
0.491
+0.020 (4.20%)
After-hours: May 31, 2024, 7:57 PM EDT
Company Description
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Quang X. Pham |
Contact Details
Address: 822 A1a North, Suite 300 Ponte Vedra, Florida 32082 United States | |
| Phone | 904-300-0701 |
| Website | cadrenal.com |
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001937993 |
| ISIN Number | US1276361086 |
| Employer ID | 88-0860746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Douglas W. Losordo FACC, FAHA, M.D. | Chief Medical Officer |
| Quang X. Pham | Chairman and Chief Executive Officer |
| Matthew K. Szot CPA, CPA | Chief Financial Officer |
| Jeffrey Cole | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 29, 2024 | PRE 14A | Other preliminary proxy statements |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 2, 2024 | EFFECT | Notice of Effectiveness |
| Apr 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 20, 2024 | EFFECT | Notice of Effectiveness |
| Mar 15, 2024 | UPLOAD | Filing |
| Mar 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |